<?xml version='1.0' encoding='utf-8'?>
<document id="26838075"><sentence text="Chronic administration of caderofloxacin, a new fluoroquinolone, increases hepatic CYP2E1 expression and activity in rats."><entity charOffset="26-40" id="DDI-PubMed.26838075.s1.e0" text="caderofloxacin" /><entity charOffset="48-63" id="DDI-PubMed.26838075.s1.e1" text="fluoroquinolone" /><pair ddi="false" e1="DDI-PubMed.26838075.s1.e0" e2="DDI-PubMed.26838075.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26838075.s1.e0" e2="DDI-PubMed.26838075.s1.e1" /></sentence><sentence text="Caderofloxacin is a new fluoroquinolone that is under phase III clinical trials in China"><entity charOffset="0-14" id="DDI-PubMed.26838075.s2.e0" text="Caderofloxacin" /><entity charOffset="24-39" id="DDI-PubMed.26838075.s2.e1" text="fluoroquinolone" /><pair ddi="false" e1="DDI-PubMed.26838075.s2.e0" e2="DDI-PubMed.26838075.s2.e0" /><pair ddi="false" e1="DDI-PubMed.26838075.s2.e0" e2="DDI-PubMed.26838075.s2.e1" /></sentence><sentence text=" Here we examined the effects of caderofloxacin on rat hepatic cytochrome P450 (CYP450) isoforms as well as the potential of caderofloxacin interacting with co-administered drugs"><entity charOffset="33-47" id="DDI-PubMed.26838075.s3.e0" text="caderofloxacin" /><entity charOffset="125-139" id="DDI-PubMed.26838075.s3.e1" text="caderofloxacin" /><pair ddi="false" e1="DDI-PubMed.26838075.s3.e0" e2="DDI-PubMed.26838075.s3.e0" /><pair ddi="false" e1="DDI-PubMed.26838075.s3.e0" e2="DDI-PubMed.26838075.s3.e1" /></sentence><sentence text="" /><sentence text="Male rats were treated with caderofloxacin (9 mg/kg, ig) once or twice daily for 14 consecutive days"><entity charOffset="28-42" id="DDI-PubMed.26838075.s5.e0" text="caderofloxacin" /></sentence><sentence text=" The effects of caderofloxacin on CYP3A, 2D6, 2C19, 1A2, 2E1 and 2C9 were evaluated using a &quot;cocktail&quot; of 6 probes (midazolam, dextromethorphan, omeprazole, theophylline, chlorzoxazone and diclofenac) injected on d 0 (prior to caderofloxacin exposure) and d 15 (after caderofloxacin exposure)"><entity charOffset="16-30" id="DDI-PubMed.26838075.s6.e0" text="caderofloxacin" /><entity charOffset="116-125" id="DDI-PubMed.26838075.s6.e1" text="midazolam" /><entity charOffset="127-143" id="DDI-PubMed.26838075.s6.e2" text="dextromethorphan" /><entity charOffset="145-155" id="DDI-PubMed.26838075.s6.e3" text="omeprazole" /><entity charOffset="157-169" id="DDI-PubMed.26838075.s6.e4" text="theophylline" /><entity charOffset="171-184" id="DDI-PubMed.26838075.s6.e5" text="chlorzoxazone" /><entity charOffset="189-199" id="DDI-PubMed.26838075.s6.e6" text="diclofenac" /><entity charOffset="227-241" id="DDI-PubMed.26838075.s6.e7" text="caderofloxacin" /><entity charOffset="268-282" id="DDI-PubMed.26838075.s6.e8" text="caderofloxacin" /><pair ddi="false" e1="DDI-PubMed.26838075.s6.e0" e2="DDI-PubMed.26838075.s6.e0" /><pair ddi="false" e1="DDI-PubMed.26838075.s6.e0" e2="DDI-PubMed.26838075.s6.e1" /><pair ddi="false" e1="DDI-PubMed.26838075.s6.e0" e2="DDI-PubMed.26838075.s6.e2" /><pair ddi="false" e1="DDI-PubMed.26838075.s6.e0" e2="DDI-PubMed.26838075.s6.e3" /><pair ddi="false" e1="DDI-PubMed.26838075.s6.e0" e2="DDI-PubMed.26838075.s6.e4" /><pair ddi="false" e1="DDI-PubMed.26838075.s6.e0" e2="DDI-PubMed.26838075.s6.e5" /><pair ddi="false" e1="DDI-PubMed.26838075.s6.e0" e2="DDI-PubMed.26838075.s6.e6" /><pair ddi="false" e1="DDI-PubMed.26838075.s6.e0" e2="DDI-PubMed.26838075.s6.e7" /><pair ddi="false" e1="DDI-PubMed.26838075.s6.e0" e2="DDI-PubMed.26838075.s6.e8" /><pair ddi="false" e1="DDI-PubMed.26838075.s6.e1" e2="DDI-PubMed.26838075.s6.e1" /><pair ddi="false" e1="DDI-PubMed.26838075.s6.e1" e2="DDI-PubMed.26838075.s6.e2" /><pair ddi="false" e1="DDI-PubMed.26838075.s6.e1" e2="DDI-PubMed.26838075.s6.e3" /><pair ddi="false" e1="DDI-PubMed.26838075.s6.e1" e2="DDI-PubMed.26838075.s6.e4" /><pair ddi="false" e1="DDI-PubMed.26838075.s6.e1" e2="DDI-PubMed.26838075.s6.e5" /><pair ddi="false" e1="DDI-PubMed.26838075.s6.e1" e2="DDI-PubMed.26838075.s6.e6" /><pair ddi="false" e1="DDI-PubMed.26838075.s6.e1" e2="DDI-PubMed.26838075.s6.e7" /><pair ddi="false" e1="DDI-PubMed.26838075.s6.e1" e2="DDI-PubMed.26838075.s6.e8" /><pair ddi="false" e1="DDI-PubMed.26838075.s6.e2" e2="DDI-PubMed.26838075.s6.e2" /><pair ddi="false" e1="DDI-PubMed.26838075.s6.e2" e2="DDI-PubMed.26838075.s6.e3" /><pair ddi="false" e1="DDI-PubMed.26838075.s6.e2" e2="DDI-PubMed.26838075.s6.e4" /><pair ddi="false" e1="DDI-PubMed.26838075.s6.e2" e2="DDI-PubMed.26838075.s6.e5" /><pair ddi="false" e1="DDI-PubMed.26838075.s6.e2" e2="DDI-PubMed.26838075.s6.e6" /><pair ddi="false" e1="DDI-PubMed.26838075.s6.e2" e2="DDI-PubMed.26838075.s6.e7" /><pair ddi="false" e1="DDI-PubMed.26838075.s6.e2" e2="DDI-PubMed.26838075.s6.e8" /><pair ddi="false" e1="DDI-PubMed.26838075.s6.e3" e2="DDI-PubMed.26838075.s6.e3" /><pair ddi="false" e1="DDI-PubMed.26838075.s6.e3" e2="DDI-PubMed.26838075.s6.e4" /><pair ddi="false" e1="DDI-PubMed.26838075.s6.e3" e2="DDI-PubMed.26838075.s6.e5" /><pair ddi="false" e1="DDI-PubMed.26838075.s6.e3" e2="DDI-PubMed.26838075.s6.e6" /><pair ddi="false" e1="DDI-PubMed.26838075.s6.e3" e2="DDI-PubMed.26838075.s6.e7" /><pair ddi="false" e1="DDI-PubMed.26838075.s6.e3" e2="DDI-PubMed.26838075.s6.e8" /><pair ddi="false" e1="DDI-PubMed.26838075.s6.e4" e2="DDI-PubMed.26838075.s6.e4" /><pair ddi="false" e1="DDI-PubMed.26838075.s6.e4" e2="DDI-PubMed.26838075.s6.e5" /><pair ddi="false" e1="DDI-PubMed.26838075.s6.e4" e2="DDI-PubMed.26838075.s6.e6" /><pair ddi="false" e1="DDI-PubMed.26838075.s6.e4" e2="DDI-PubMed.26838075.s6.e7" /><pair ddi="false" e1="DDI-PubMed.26838075.s6.e4" e2="DDI-PubMed.26838075.s6.e8" /><pair ddi="false" e1="DDI-PubMed.26838075.s6.e5" e2="DDI-PubMed.26838075.s6.e5" /><pair ddi="false" e1="DDI-PubMed.26838075.s6.e5" e2="DDI-PubMed.26838075.s6.e6" /><pair ddi="false" e1="DDI-PubMed.26838075.s6.e5" e2="DDI-PubMed.26838075.s6.e7" /><pair ddi="false" e1="DDI-PubMed.26838075.s6.e5" e2="DDI-PubMed.26838075.s6.e8" /><pair ddi="false" e1="DDI-PubMed.26838075.s6.e6" e2="DDI-PubMed.26838075.s6.e6" /><pair ddi="false" e1="DDI-PubMed.26838075.s6.e6" e2="DDI-PubMed.26838075.s6.e7" /><pair ddi="false" e1="DDI-PubMed.26838075.s6.e6" e2="DDI-PubMed.26838075.s6.e8" /><pair ddi="false" e1="DDI-PubMed.26838075.s6.e7" e2="DDI-PubMed.26838075.s6.e7" /><pair ddi="false" e1="DDI-PubMed.26838075.s6.e7" e2="DDI-PubMed.26838075.s6.e8" /></sentence><sentence text=" Hepatic microsomes from the caderofloxacin-treated rats were used to assess CYP2E1 activity and chlorzoxazone metabolism"><entity charOffset="29-43" id="DDI-PubMed.26838075.s7.e0" text="caderofloxacin" /><entity charOffset="97-110" id="DDI-PubMed.26838075.s7.e1" text="chlorzoxazone" /><pair ddi="false" e1="DDI-PubMed.26838075.s7.e0" e2="DDI-PubMed.26838075.s7.e0" /><pair ddi="false" e1="DDI-PubMed.26838075.s7.e0" e2="DDI-PubMed.26838075.s7.e1" /></sentence><sentence text=" The expression of CYP2E1 mRNA and protein in hepatic microsomes was analyzed with RT-PCR and Western blotting, respectively" /><sentence text="" /><sentence text="Fourteen-day administration of caderofloxacin significantly increased the activity of hepatic CYP2E1, leading to enhanced metabolism of chlorzoxazone"><entity charOffset="31-45" id="DDI-PubMed.26838075.s10.e0" text="caderofloxacin" /><entity charOffset="136-149" id="DDI-PubMed.26838075.s10.e1" text="chlorzoxazone" /><pair ddi="false" e1="DDI-PubMed.26838075.s10.e0" e2="DDI-PubMed.26838075.s10.e0" /><pair ddi="false" e1="DDI-PubMed.26838075.s10.e0" e2="DDI-PubMed.26838075.s10.e1" /></sentence><sentence text=" In vitro microsomal study confirmed that CYP2E1 was a major metabolic enzyme involved in chlorzoxazone metabolism, and the 14-d administration of caderofloxacin significantly increased the activity of CYP2E1 in hepatic microsomes, resulting in increased formation of 6-hydroxychlorzoxazone"><entity charOffset="90-103" id="DDI-PubMed.26838075.s11.e0" text="chlorzoxazone" /><entity charOffset="147-161" id="DDI-PubMed.26838075.s11.e1" text="caderofloxacin" /><entity charOffset="268-290" id="DDI-PubMed.26838075.s11.e2" text="6-hydroxychlorzoxazone" /><pair ddi="false" e1="DDI-PubMed.26838075.s11.e0" e2="DDI-PubMed.26838075.s11.e0" /><pair ddi="false" e1="DDI-PubMed.26838075.s11.e0" e2="DDI-PubMed.26838075.s11.e1" /><pair ddi="false" e1="DDI-PubMed.26838075.s11.e0" e2="DDI-PubMed.26838075.s11.e2" /><pair ddi="false" e1="DDI-PubMed.26838075.s11.e1" e2="DDI-PubMed.26838075.s11.e1" /><pair ddi="false" e1="DDI-PubMed.26838075.s11.e1" e2="DDI-PubMed.26838075.s11.e2" /></sentence><sentence text=" Furthermore, the 14-d administration of caderofloxacin significantly increased the expression of CYP2E1 mRNA and protein in liver microsomes, which was consistent with the pharmacokinetic results"><entity charOffset="41-55" id="DDI-PubMed.26838075.s12.e0" text="caderofloxacin" /></sentence><sentence text="" /><sentence text="Fourteen-day administration of caderofloxacin can induce the expression and activity of hepatic CYP2E1 in rats"><entity charOffset="31-45" id="DDI-PubMed.26838075.s14.e0" text="caderofloxacin" /></sentence><sentence text=" When caderofloxacin is administered, a potential drug-drug interaction mediated by CYP2E1 induction should be considered"><entity charOffset="6-20" id="DDI-PubMed.26838075.s15.e0" text="caderofloxacin" /></sentence><sentence text="" /></document>